Genetics Institute Inc v Kirin-Amgen Inc (No. 3)

The parties involved in the case were Genetics Institute Inc, the appellant, and Kirin-Amgen Inc, the respondent. The dispute arose from a patent application concerning erythropoietin, a hormone used in the treatment of anaemia. The case was heard in the Federal Court of Australia. The central issue before the court was whether the patent application should be amended and, if so, to what extent. Specifically, the court needed to determine whether certain deletions and modifications to the application would be appropriate.

The court was tasked with examining the proposed amendments to the patent application and deciding if they complied with the relevant patent laws and regulations. The appellant argued that the amendments were necessary to correct errors and ensure clarity, while the respondent contended that the changes would broaden the scope of the patent in an impermissible way. The court had to balance the need for accuracy in patent specifications against the potential for overreach in patent claims.

In its reasoning, the court found that certain amendments were necessary to correct inaccuracies in the patent application. The court agreed with the deletion of a specific passage and claim 39, as these were deemed to be overly broad and not aligned with the original intent of the patent. However, the court rejected other proposed changes, finding them to be unnecessary or inappropriate. The court concluded that the application should be amended in accordance with the specified changes but dismissed the broader amendments proposed by the appellant. The court also ordered that the appellant pay a significant portion of the respondent’s costs associated with the appeal.